We recently published a list of Jim Cramer Reacts to the Surprise Market Surge and Highlights 8 Key Stocks In this article, ...

Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

Amar Vennapusa, a bariatric surgeon, fills a syringe with Eli Lilly's Mounjaro, a tirzepatide injection drug used for ...

The drugmaker said one patient became ill after being treated with its experimental weight-loss drug, danuglipron.

A number of stocks fell in the afternoon session after stocks gave back some of the gains from the previous day as the White ...

After massive gains in the past five years on the heels of the weight loss blockbuster Zepbound, Eli Lilly & Co (LLY) stock ...

The Dow and S&P 500 wavered between gains and losses at midday Wednesday amid heightened volatility after the U.S. imposed ...

We recently published a list of 10 Best Pharma Stocks to Buy for Long Term Growth. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other best ...

In a report released on April 9, Tim Anderson from Bank of America Securities maintained a Buy rating on Eli Lilly and ...

We recently published a list of the 10 High Growth Forever Dividend Stocks to Invest In. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against other ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

The implications for Eli Lilly and Novo Nordisk seem pretty clear: The immediate removal of a rival for the massive revenues ...